What it means
Drug development is long, costly and uncertain. A candidate must go through laboratory work, trials in people in several phases and a regulatory review before it can be sold.
Many candidates fail along the way, so the money spent on them is lost. For a finance professional, a drug is both a product and an asset.
Before approval, spending on it is typically treated as research and development expense. After approval, the company may sell it for years, usually supported by patents that stop competitors from copying it for a period.
The most important driver of value is the probability of success. Each stage of testing has a different chance of passing, and a drug in early trials is far less likely to reach the market than one in late trials.
Analysts multiply expected future profit by the probability of reaching each stage to estimate a risk-adjusted value. Patent protection and competition also shape returns.
When patents expire, generic versions can enter at much lower prices and the original company's sales often fall quickly, a pattern known as the patent cliff. Companies respond by developing new drugs, extending protection where the law allows and focusing on the products that earn the highest margins.
Pricing, insurance coverage and government rules affect revenue too. The price a company can charge depends on the country, the buyers and the evidence for the drug's benefit.
Finance teams model these factors alongside manufacturing costs and the cost of selling to doctors and health systems. Accounting treatment varies by stage and by how the drug was obtained.
Development costs incurred by the company itself are often expensed until strict conditions are met, while a drug project bought in an acquisition is recorded at its fair value as an intangible asset. This difference means that two companies with similar drugs can show very different balance sheets.
In practice
Real-world examples.
Example
A biotech company has one drug in late-stage trials and little cash. An investor values the company mainly on the risk-adjusted value of that drug, and the share price moves sharply when trial results are announced. A failed trial can wipe out most of the company's value in a single morning.
Example
A large pharmaceutical group buys a small company for $2,000,000,000 to gain access to its cancer drug. The finance team records the acquired development project as an intangible asset and tests it regularly to check that the value has not fallen. If the drug fails a trial, the asset is written down immediately.
Example
A drug maker faces the loss of patent protection on a product that earns $3,000,000,000 a year. The planning team models a sharp fall in sales after generic competitors arrive, and sets a target to replace the lost revenue with new products.
Formula
Calculation
Risk-adjusted value of a drug candidate = (Probability of approval x Value if approved) - Remaining development cost
Suppose a candidate has a 20% chance of reaching the market. If approved, the present value of its future profit would be $500,000,000, and the remaining development cost is $40,000,000. Expected value of success = 0.20 x 500,000,000 = $100,000,000. Risk-adjusted value = 100,000,000 - 40,000,000 = $60,000,000. This is a simplified method that treats all costs as certain and ignores the timing of spending at different stages.Case study
Seen in the real world.
Meridian Biologics is an illustrative, fictional company with a single drug candidate for a rare skin condition. It needed $60,000,000 to finish the trials, and the founders asked investors to value the company.
An analyst estimated a 30% chance of approval and a present value of $400,000,000 if approved. The expected value was 0.30 x 400,000,000 = $120,000,000, less $60,000,000 of cost, giving a risk-adjusted value of $60,000,000.
The illustrative investors agreed to fund the trials in stages, releasing money only as each phase succeeded. This limited their loss if the drug failed, and the founders accepted that the valuation would be revised after each result. Each new tranche was priced higher if the previous phase had succeeded.
Watch out
Common mistakes.
- Valuing a drug candidate as if it were certain to reach the market, ignoring the high failure rate during development.
- Assuming sales continue at the same level after patents expire, when generic competition usually cuts revenue sharply.
- Treating all development spending as an asset, when accounting rules often require research costs to be expensed until specific conditions are met.
Questions
People also ask.
Why do drug companies spend so much on development?
Developing a drug is expensive and most candidates fail, so successful products must earn enough to pay for the many that do not.
What is a patent cliff?
It is the sharp drop in revenue that can occur when patent protection ends and cheaper generic versions are launched.
How do investors value a drug before approval?
They usually estimate the chance of approval and the future profit, then discount for risk and time, often using a risk-adjusted net present value model.
From the founder's library
Take it further with the book.
Build your financial confidence beyond this definition. Shihan's full-length guide, Accounting Fundamentals, takes the same plain-English approach and turns it into a complete, practical playbook for non-finance managers, business owners and students - with chapter-end quiz answers and presentation slides included.
25% off with code MMHQ25, applied at checkout. Priced in USD - checkout may show the equivalent in your local currency.
View the book and save 25%Related